Current Studies

The following is a list of our current studies at the Asthma Research Center. All studies are open for enrollment, unless otherwise noted. The Asthma Research Center runs multiple studies and each study varies in duration and compensation is up to $1650 for your time and effort. To see if you are eligible for any of our studies, please contact us at 617-732-8201 or via e-mail at ARC@partners.org. You can also click here to fill out a form and see if you qualify to participate.

Severe Persistent Asthma Study

This research study is testing an investigational medication.  The purpose of the study is to examine its effectiveness in treating asthma.  This medication is not yet approved by the Food and Drug Administration (FDA), so can only be used in research studies.  The medication was designed to help patients who have moderate to severe asthma symptoms, despite already being on medication.  Due to the fact asthma is an inflammatory disease of the airway, this medication targets some of the cells believe to cause that inflammation.

Participants will have 15 study visits over about a 7 month period. Participants will receive either the study medication or placebo (something that looks like the medication but contains no active medicine) at no cost and will be compensated for time and travel.  Eligible volunteers should be between 18 and 75 years of age, and have asthma symptoms despite medications such as Symbicort®, Advair® or Dulera. Your participation is voluntary. For more information, please fill out our online survey here and/or contact us at 1-888-99-ASTHMA, or email us at ARC@partners.org.

Ifetroban Study

Do you have asthma, nasal polyps, and Samter’s Triad or Aspirin-Exacerbated Respiratory Disease (AERD)? If you would like to undergo an aspirin desensitization to help treat your symptoms, you may be eligible for a research study at Brigham and Women’s Hospital testing a new medication for the treatment of AERD.

The study drug, called ifetroban, inhibits the thromboxane receptor, which we believe plays a role in AERD. This drug has not yet been approved by the Food and Drug Administration (FDA).

To qualify for the study, you have to be 18-65 years old, have symptoms consistent with Samter’s Triad/AERD, and have asthma. The study involves 3 visits over an 8-week period and involves an aspirin desensitization procedure, blood and nose fluid sampling, and urine tests. You will be seen by a medical doctor and will receive the study medication at no cost.

The purpose of this study is to find out if taking ifetroban will help treat the symptoms of AERD and prevent reactions to aspirin. Compensation is up to $225. For more information, please contact the Asthma Research Center at 1-888-99-ASTHMA (278462) or Dr. Tanya Laidlaw at tlaidlaw@partners.org.

Steroids in Eosinophil Negative Asthma (SIENA)

The SIENA study is being performed to determine if the cells present in the airway affect whether inhaled corticosteroids work or not for people. The study involves 10-13 study visits over 42 weeks and participants will be receiving inhaled steroids or a placebo during the research study. This study takes place at the Asthma Research Center within Brigham and Women’s Hospital and participants will be compensated up to $695. Eligible volunteers should be adults over the age of 18, and be taking short acting medications such as ProAir, Albuterol, Proventil, Ventolin, or Xopenex. For more information, please contact us at 1-888-99-ASTHMA, 617-732-8201 or email us at ARC@partners.org.This study is closed to enrollment and not recruiting any new patients.

Best African American Response to Asthma Drugs (BARD)

African Americans suffer a disproportionate burden of asthma morbidity compared to the general population, along with more asthma-related urgent care visits and higher rates of hospitalizations. It is known that African American/Black people with asthma sometimes don’t get better when they take the usual dose and type of medications like inhaled corticosteroids (“inhaled steroids”) used commonly to treat asthma.

We are doing this research study to find which additional asthma treatment works best for African American/Black people who have asthma that is not well controlled on a low dose inhaled steroid. We also want to find out if African American/Black people respond differently to how these medications work. Participants will include asthmatics who self-report African ancestry. This study is closed to enrollment and not recruiting any new patients.

Severe Asthma Research Program (SARP)

In recent years scientists have learned more about the way mild-to-moderate asthma works and the reasons people get it. However, scientists are still trying to figure out what makes severe asthma different and how they can do better to treat the disease.

One reason the study of severe asthma is difficult is that there are not as many people with severe asthma. In fact they make up less than 10% of people with asthma. The Severe Asthma Research Program or SARP is a national research program created so that scientists in many locations across the country can run a single, important study, and together find enough volunteers with severe asthma to participate.

The Severe Asthma Research Program (SARP) at the BWH in Boston is looking for adults taking inhaled corticosteroids who have been told they have asthma by a doctor. The observational study involves coming to our research center 6 – 8 times over the course of about 3 years. Participants will take their usual asthma medications throughout, and, as with all our studies, compensation for time spent in our center is provided. This study is closed to enrollment and not recruiting any new patients.


© 2007-2012 BWH Asthma Research Center